MEDI 1814

Drug Profile

MEDI 1814

Alternative Names: MEDI-1814

Latest Information Update: 14 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 09 Dec 2016 AstraZeneca and Eli Lilly agree to co-develop MEDI 1814 for Alzheimer’s disease
  • 01 Sep 2016 AstraZeneca completes a phase I trial for Alzheimer's disease in the US (NCT02036645)
  • 13 Oct 2015 Phase-I development is ongoing for Alzheimer's disease in USA (NCT02036645)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top